MPC-Mediated Lactate Production and Histone Lactylation in Tumor Immunity

Study Background and Research Question

Metabolic reprogramming is a hallmark of cancer, enabling tumor cells to adapt and thrive in adverse microenvironments. One of the most prominent features is increased aerobic glycolysis (the Warburg effect), leading to elevated lactate levels and acidification of the tumor microenvironment (TME). Lactate, once considered a metabolic byproduct, is now recognized as a central modulator of immune cell function, gene expression, and tumor progression. Recent evidence suggests that lactate can also act as a signaling molecule, modifying proteins via post-translational modifications such as histone lactylation. However, the precise molecular mechanisms linking metabolic alterations to immune suppression remain incompletely understood. The study by Zhang et al. (Cellular and Molecular Life Sciences, 2025) addresses this gap by investigating how mitochondrial pyruvate carrier (MPC) subunits MPC1 and MPC2 regulate lactate production, histone lactylation in dendritic cells (DCs), and subsequent effects on tumor progression and immunotherapy efficacy.

Key Innovation from the Reference Study

The central innovation of this research lies in connecting MPC-mediated metabolic flux to epigenetic regulation of dendritic cell maturation and antitumor immunity. Specifically, the authors demonstrate that downregulation of MPC1 and MPC2 in colorectal cancer (CRC) cells elevates lactate production, which in turn enhances histone lactylation. This epigenetic modification alters the transcriptional landscape of DCs, reducing expression of CD33 (a marker of DC maturation), ultimately impairing CD8+ T cell responses. Importantly, restoring MPC activity not only reduces lactate and histone lactylation but also sensitizes tumors to anti-PD-1 immunotherapy, revealing a direct link between metabolic state, epigenetic modulation, and immune evasion.

Methods and Experimental Design Insights

The authors employed a comprehensive suite of approaches to dissect the metabolic-epigenetic-immune axis. Key methodologies included:

• Patient sample analysis: Expression of MPC1/2 was assessed in clinical CRC specimens, revealing significant downregulation compared to normal tissue.
• Genetic manipulation: CRC cell lines were engineered for overexpression or knockdown of MPC1/2 to evaluate effects on lactate production and tumor cell phenotypes.
• In vitro functional assays: Cell proliferation, migration, and invasion assays established the impact of MPC modulation on tumor aggressiveness.
• In vivo tumor models: CRC cells with altered MPC expression were implanted in mice to assess tumor growth and response to anti-PD-1 therapy.
• Biochemical and molecular analyses: Quantification of lactate, histone lactylation (lysine lactylation, Kla), and expression of DC maturation markers (notably CD33) were performed. Co-culture systems with DCs and T cells enabled functional immunological assessments.

This multi-pronged strategy provided mechanistic clarity and translational relevance, linking metabolic changes to epigenetic and immunological outcomes.

Core Findings and Why They Matter

The major findings of the study are as follows:

• MPC1/2 downregulation is common in CRC: Reduced MPC expression was observed in patient tumors, correlating with increased lactate levels and aggressive tumor behavior (reference).
• Elevated lactate drives histone lactylation: High lactate in the TME increases global histone lactylation in DCs, altering gene expression profiles relevant to immune function.
• Epigenetic control of DC maturation: Lactate-induced histone lactylation reduces CD33 expression, leading to impaired maturation of DCs. This, in turn, dampens the activation and cytotoxicity of CD8+ T cells.
• Therapeutic implications: Overexpression of MPC1/2 in CRC cells lowered lactate, reduced histone lactylation, restored DC function, and potentiated the effects of anti-PD-1 therapy in mouse models.

These results underscore the importance of metabolic-epigenetic crosstalk in shaping the immune landscape of tumors. Targeting the lactate axis—either by modulating MPC activity or inhibiting downstream enzymes such as LDH—may thus enhance immunotherapy response by reprogramming both tumor and immune cell states.

Comparison with Existing Internal Articles

Recent internal guides and reviews have highlighted the relevance of metabolic inhibitors in immunometabolic assays. For example, Stiripentol: Unraveling LDH Inhibition for Epigenetic and Immune Modulation discusses the utility of Stiripentol as a noncompetitive LDH inhibitor for probing lactate-dependent processes, including histone lactylation and immune regulation. This aligns with Zhang et al.'s findings that interrupting the lactate-to-pyruvate conversion (via LDH or upstream interventions) can impact immune cell maturation and tumor progression. Additionally, workflow-driven articles such as Stiripentol (SKU A8704): Reliable LDH Inhibition in Cell- and Immunometabolic Assays provide scenario-based protocols for implementing LDH inhibitors in cell viability and TME studies, reinforcing the translational potential of metabolic interventions for immunotherapy research. These resources emphasize rigorous experimental design and interpretation when targeting lactate metabolism, supporting the mechanistic insights illuminated by the reference study.

Limitations and Transferability

While the study robustly demonstrates a mechanistic link between MPC downregulation, lactate accumulation, histone lactylation, and immune evasion in CRC models, several limitations should be noted:

• Tumor specificity: The findings are centered on colorectal cancer; applicability to other tumor types with distinct metabolic and immunological landscapes requires validation.
• Model systems: While both in vitro and in vivo data are presented, mouse models may not fully recapitulate the complexity of human TME interactions.
• Clinical translation: The potential for targeting MPC or lactate metabolism in patients needs further investigation, particularly regarding safety, specificity, and combination with immunotherapies.

Nevertheless, the study provides a strong framework for exploring metabolic-epigenetic regulation of immunity in cancer and suggests actionable hypotheses for preclinical and translational research.

Protocol Parameters

• MPC modulation in vitro: Transfect CRC cells with MPC1/2 overexpression vectors or siRNAs for knockdown; verify by qPCR and immunoblotting.
• Lactate and histone lactylation assays: Measure extracellular and intracellular lactate using enzymatic or LC-MS-based assays; assess histone lactylation via Western blot with anti-Kla antibodies.
• Dendritic cell co-culture: Culture DCs with tumor-conditioned media or direct co-culture to analyze maturation markers (e.g., CD33) and functional readouts.
• In vivo model parameters: Implant genetically manipulated CRC cells subcutaneously in immunocompetent mice; administer anti-PD-1 antibody following established dosing schedules.
• LDH inhibitor application (literature guidance): For researchers seeking to modulate the astrocyte-neuron lactate shuttle or TME lactate flux, noncompetitive LDH inhibitors such as Stiripentol can be applied at concentrations validated for cell-based models (see product specifications and internal workflow guides for recommended solubilization and dosing).

Research Support Resources

To facilitate experimental studies of lactate metabolism, histone lactylation, and immunometabolic modulation, researchers can select reagents such as Stiripentol (SKU A8704) from APExBIO. As a noncompetitive LDH inhibitor, Stiripentol enables precise inhibition of lactate-to-pyruvate conversion, supporting workflows that interrogate the metabolic and epigenetic axes described in this study. For guidance on assay setup, solubility in DMSO or ethanol, and recommended storage, refer to the product information and scenario-driven protocols available through APExBIO and relevant internal resources. These tools can support rigorous exploration of lactate-driven immune and epigenetic mechanisms in oncology and beyond.